Exscientia to merge operations with Recursion from the US in a $668m deal
02 August 2024
02 August 2024
Total investments received (USD): 203.88m
Round value (USD): 668m
Company: Exiscientia
Related deals
Verdiva Bio raised $410m in Series A funding co-led by Forbion and General Atlantic
Investments
10 December 2024
Purespring Therapeutics raised £80M series B led by Sofinnova Partners, joined by British Patient Capital, Syncona, Gilde Healthcare and Forbion.
Investments
02 October 2024
Vicebio raised $100M with TCG Crossover, venBio Partners, UniQuest, Medicxi, Goldman Sachs Alternatives and Avoro Ventures
Investments
17 September 2024
F2G raised a $100m round co-led AMR Action Fund and ICG, joined by Novo, Advent Life, Sofinnova, Forbion, Blue Owl, Morningside, and Merifin Capital.
Investments
01 September 2024
Myricx Bio raised $114m in Series A funding co-led by Abingworth and Novo Holdings, joined by insiders Brandon Capital and Sofinnova Partners.
Investments
01 July 2024
Austria
Germany
Switzerland
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden
Ireland
Italy
Portugal
Spain